Pentamethyl Melamine

Pentamethyl Melamine

SCHEMBL38832

CNc1nc(N(C)C)nc(N(C)C)n1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.61
CYP1A2 P05177 1/20 0.61
THRB P10828 1/20 0.61
BLM P54132 1/20 0.61
CREBBP Q92793 1/20 0.61
HSD17B10 Q99714 1/20 0.61
POLB P06746 1/20 0.52
ALDH1A1 P00352 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PDE4A P27815 1/20 0.47
OPRM1 P35372 1/20 0.41
OPRL1 P41146 1/20 0.41
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
IDH2 P48735 1/20 0.37
GAA P10253 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Altretamine SCHEMBL4448907 1.00 LMNA (0.61) LMNACYP1A2THRBBLMCREBBP
Pentamethyl Melamine SCHEMBL15346326 0.97 LMNA (0.58) LMNACYP1A2THRBBLMCREBBP
SCHEMBL1033226 0.94 CYP1A2 (0.53) LMNACYP1A2THRBBLMCREBBP
SCHEMBL13599448 0.85 PDE4A (0.46) LMNACYP1A2THRBBLMCREBBP
Altretamine SCHEMBL1978783 0.84 LMNA (0.48) LMNACYP1A2THRBBLMCREBBP
SCHEMBL60190 0.84 LMNA (0.42) LMNACYP1A2THRBBLMCREBBP
SCHEMBL11556026 0.84 PDE4A (0.48) LMNACYP1A2THRBBLMCREBBP
SCHEMBL18737196 0.84 PDE4A (0.45) LMNACYP1A2THRBBLMCREBBP
SCHEMBL3234910 0.83 LMNA (0.42) LMNACYP1A2THRBBLMCREBBP
SCHEMBL9988581 0.80 POLB (0.50) LMNACYP1A2THRBBLMCREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3120 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326859-A1 ANTI-CANCER ANTIBODIES, COMBINATION THERAPIES, AND USES THEREOF PREC BIOLOGICS INC (US) 2025-10-23 US claimed
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US claimed
WO-2025064690-A1 HIGH AFFINITY ANTIBODIES RECOGNIZING CORE 2 O-GLYCANS OF VARIANT MUC5AC ANTIGEN, COMPOSITIONS CONTAINING AND USES THEREOF PRECISION BIOLOGICS, INC. (US) 2025-03-27 WO claimed
CN-110357825-B Improved co-production of pentahydroxy and hexamethylol melamine 重庆建峰浩康化工有限公司 2023-01-24 CN claimed
US-11560352-B2 P62-ZZ small molecule modulators University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2023-01-24 US claimed
WO-2022169634-A9 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-09-22 WO claimed
WO-2022169634-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-08-11 WO claimed
US-11279768-B1 Anti-cancer antibodies, combination therapies, and uses thereof PRECISION BIOLOGICS, INC. (US) 2022-03-22 US claimed
US-11058687-B2 Human papilloma virus as predictor of cancer prognosis FOUNDATION MEDICINE, INC. (US) 2021-07-13 US claimed
CN-107540803-B Method for synthesizing butylated amino resin by using pentamethyl melamine 重庆建峰浩康化工有限公司 2021-03-23 CN claimed
EP-1206252-A1 AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS BIOTECH AUSTRALIA PTY. LIMITED (AU) 2002-05-22 EP claimed
EP-1206251-A1 AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES BIOTECH AUSTRALIA PTY. LIMITED (AU) 2002-05-22 EP claimed
EP-0668782-B1 COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER UNIV TEMPLE (US) 2001-04-11 EP claimed
WO-2000074721-A1 VITAMIN DIRECTED DUAL TARGETING THERAPY BIOTECH AUSTRALIA PTY LIMITED (AU) 2000-12-14 WO claimed
WO-2000066091-A1 AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS BIOTECH AUSTRALIA PTY LIMITED (AU) 2000-11-09 WO claimed
WO-2000066090-A1 AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES BIOTECH AUSTRALIA PTY LIMITED (AU) 2000-11-09 WO claimed
WO-1997032589-A1 COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 1997-09-12 WO claimed
WO-1997032604-A1 ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS NOVARTIS AG (CH) 1997-09-12 WO claimed
EP-0668782-A1 COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1995-08-30 EP claimed
WO-1994008625-A1 COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1994-04-28 WO claimed